Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response: 0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*  Westby Keith					2. Issuer Name and Ticker or Trading Symbol IVERIC bio, Inc. [ ISEE ]									Check	all app	o of Reportir licable) tor er (give title	ng Per	rson(s) to Is 10% O Other (	wner
(Last) (First) (Middle) C/O IVERIC BIO, INC.					3. Date of Earliest Transaction (Month/Day/Year) 02/15/2022									X	below)		below)		speen,
8 SYLVAN WAY  (Street) PARSIPPANY NJ 07054  (City) (State) (Zip)				4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Indiv Line) X	′					
		Table	1 - 1	Non-Deriva	tive	Secui	rities	Ac	quir	ed, Di	isposed o	of, or I	Benefic	ially	Own	ed			
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Yea				ar) E	2A. Deemed Execution Date, if any (Month/Day/Year		1	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar			nd 5) Secu Bene		icially d Following	Forn (D) o	ect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							(	Code	v	Amount	(A) or (D)	Price		Transa	ransaction(s) nstr. 3 and 4)		4)	(mour 4)	
Common Stock 02/15/202			02/15/202	2			S <sup>(1)</sup>		10,000	D	\$15.1634(2)		108,280			D			
		Tal	ble	II - Derivati (e.g., pu							posed of converti				Owne	d			
1. Title of Derivative Security (Instr. 3)	erivative conversion or Exercise (Month/Day/Year) str. 3) Date (Month/Day/Year) Price of Derivative Security  Execution Date, if any (Month/Day/Year)			4. Transa Code 8)		5. Num of Deriva Secur Acqui (A) or Dispo of (D) (Instr. and 5	ative rities ired sed	Expiration Date (Month/Day/Year)			Amo Secu Unde Deriv Secu 3 and	Amount or Number of	nt er		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	

## **Explanation of Responses:**

- 1. The sale reported on this form was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2021.
- 2. The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from \$15.0000 to \$15.3200 per share on February 15, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range.

## Remarks:

/s/ Todd Anderman, as attorney-in-fact for Keith

02/16/2022

Westby

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.